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Abstract
Background: Elevated levels of type I interferons (IFNs) are a characteristic feature of the systemic autoimmune
rheumatic diseases (SARDs) and are thought to play an important pathogenic role. However, it is unknown whether
these elevations are seen in anti-nuclear antibody–positive (ANA+) individuals who lack sufficient criteria for a SARD
diagnosis. We examined IFN-induced gene expression in asymptomatic ANA+ individuals and patients with
undifferentiated connective tissue disease (UCTD) to address this question.
Methods: Healthy ANA− control subjects and ANA+ titre (≥1:160 by immunofluorescence) participants meeting no
criteria, meeting at least one criterion (UCTD) or meeting SARD classification criteria were recruited. Whole
peripheral blood IFN-induced and BAFF gene expression were quantified using NanoString technology. The
normalized levels of five IFN-induced genes were summed to produce an IFN5 score.
Results: The mean IFN5 scores were increased in all ANA+ participant subsets as compared with healthy control
subjects. We found that 36.8% of asymptomatic ANA+ and 50% of UCTD participants had IFN5 scores >2 SD above
the mean for healthy control subjects. In all ANA+ subsets, the IFN5 score correlated with the presence of anti-Ro/
La antibodies. In the asymptomatic ANA+ subset, this score also correlated with the ANA titre, whereas in the other
ANA+ subsets, it correlated with the number of different ANA specificities. Development of new SARD criteria was
seen in individuals with normal and high IFN5 scores.
Conclusions: An IFN signature is seen in a significant proportion of ANA+ individuals and appears to be associated
with ANA titre and type of autoantibodies, rather than with the presence or development of clinical SARD
symptoms.
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Background
The systemic autoimmune rheumatic diseases (SARDs)
that are frequently associated with a positive anti-
nuclear antibody (ANA) test result include systemic
lupus erythematosus (SLE), Sjögren’s syndrome (SS), sys-
temic sclerosis (SSc), dermatomyositis (DM) and mixed
connective tissue disease (MCTD). Although each of
these conditions constitutes a distinct clinical syndrome,
they all share a similar etiopathogenesis based upon
their overlapping clinical features, co-segregation within
families and shared production of ANAs [1–4]. One of
the characteristic features of these conditions is a pro-
longed pre-clinical phase during which autoantibodies
can be detected in the absence of clinical disease. In
SLE, autoantibodies can be detected up to 9 years before
development of clinical symptoms [5], and similar obser-
vations have been made in SSc and SS [6, 7]. Because
the onset of clinical symptoms in these conditions can
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be associated with significant morbidity, and occasion-
ally mortality, there is tremendous interest in identifying
and treating patients with SARD earlier in their disease
course [8, 9]. However, a major impediment to this ap-
proach is the observation that ANAs can also be seen in
healthy individuals, particularly women, most of whom
will not progress to SARD [10]. Thus, there is a need for
additional biomarkers that can accurately predict indi-
viduals with a high likelihood of progression to SARD.
A number of immunologic changes have been ob-
served at the onset of SARD. One of the most distinctive
immunologic abnormalities is high levels of interferon
(IFN)-induced gene expression, the so-called IFN signa-
ture [11–16]. Although initially described in patients
with SLE, this signature was subsequently reported for
all SARDs, with multiple lines of evidence suggesting
that elevated levels of type I IFNs play an important
pathogenic role in these conditions. Types II and III
IFNs can also induce this signature, and there is emer-
ging evidence that they may also play a role in disease
pathogenesis [17]. Currently, it is not known whether in-
dividuals who are ANA+ who either lack symptoms or
have insufficient symptoms to diagnose a SARD have an
IFN signature. In this study, we assessed IFN-induced
gene expression in these individuals and examined the
serologic and clinical correlates.
Methods
Subjects and data collection
ANA+ individuals (titre ≥1:160 by immunofluorescence)
were recruited at the Toronto Western and Mount Sinai
hospitals, where they were assessed by one of the partici-
pating rheumatologists. The majority of patients were
referred to these clinics because they had a recent posi-
tive ANA test result at an outside laboratory with or
without rheumatologic symptoms. All clinical data were
obtained through the use of a standardized question-
naire and a data retrieval form that elicited all of the
clinical symptoms and signs required for disease classifi-
cation. On the basis of their clinical and laboratory find-
ings at their initial assessments, participants were
stratified into three groups: (1) asymptomatic ANA+ in-
dividuals lacking any clinical symptoms of SARD, (2) pa-
tients with undifferentiated connective tissue disease
(UCTD) with at least one clinical symptom of SARD
and (3) patients with early SARD meeting classification
criteria (1997 American College of Rheumatology [ACR]
criteria for SLE [18], 2013 ACR-European League
Against Rheumatism [EULAR] criteria for SSc [19] or
the revised American-European criteria for SS [20]) and
who had received their diagnosis within the previous
2 years. To avoid inclusion of patients with long-
standing disease who had only recently been diagnosed
with SS on the basis of the established criteria, only
patients whose symptoms had begun within the previous
5 years were included in the study. All patients were
steroid-naïve and off disease-modifying anti-rheumatic
drugs (DMARDs), with the exception of anti-malarials.
Age- and sex-matched healthy control subjects (HC) were
recruited from among hospital/laboratory personnel and
were ANA- and specific anti-nuclear autoantibody- nega-
tive. The study was approved by the research ethics boards
of both recruiting hospitals, and all participants signed in-
formed consent forms.
RNA isolation and performance of NanoString
Total RNA was isolated from whole peripheral blood
archived in Tempus tubes using a Tempus Spin RNA
Isolation Kit (Applied Biosystems, Foster City, CA,
USA) following the manufacturer’s instructions. Gene
expression was quantified using NanoString technology
with 100 ng of RNA in a custom array (NanoString
Technologies, Seattle, WA, USA) at the Farncombe Meta-
genomics Facility (McMaster University, Hamilton, ON,
Canada). The expression levels of five IFN-induced genes
(EPSTI1, IFI44L, LY6E, OAS3, and RSAD2) that were pre-
viously reported to be induced by IFN-α and ubiquitously
expressed in multiple cell types were measured and
summed to generate an IFN5 score, which was used as
the primary measure of an IFN signature. Expression of
two IFN-induced genes that are reported to indicate
stronger IFN-induced gene induction (EIF2AK2 and
PLSCR1) and BAFF were also assessed. Raw expression
levels of all genes were normalized to expression of five
housekeeping genes (FPGS, HPRT1, GAPDH, PPIB, and
TBP) using nSolver software (NanoString Technologies).
Measurement of autoantibodies
All participants had their ANA quantified by indirect
immunofluorescence with serum obtained at the time
of recruitment through the University Health Network
laboratory, which uses HEp-2 cells as a substrate. Only
individuals with an ANA titre ≥1:160 at this determin-
ation were included in the ANA+ study cohorts. The
serum levels of ten specific autoantibodies (anti-
double-stranded DNA [anti-dsDNA], anti-chromatin,
anti-Ro, anti-La, anti-Smith [anti-Sm], anti-Sm/RNP,
anti-ribonuclear protein [anti-RNP], anti-Jo-1, anti-Scl-
70 and anti-centromere) were assayed by the BioPlex®
2200 ANA Screening System (Bio-Rad Laboratories,
Hercules, CA, USA) in the hospital laboratory using
the manufacturer’s cut-offs. Healthy control subjects
with an ANA titre ≥1:160 were re-classified into the
asymptomatic ANA+ group (25.7% of female and 0% of
male healthy control subjects recruited) and those with
a positive ANA at a titre <1:160 or any specific auto-
antibodies (8.6% of female and 0% of male healthy con-
trol subjects recruited) were excluded from the study.
Wither et al. Arthritis Research & Therapy  (2017) 19:41 Page 2 of 11
Measurement of serum IFN-α
Serum archived at the time of recruitment was stored
at −80 °C and thawed immediately prior to testing.
Serum levels of IFN-α were measured in duplicate
using the VeriKine-HS Human Interferon Alpha All
Subtype ELISA Kit (PBL Assay Science, Piscataway,
NJ, USA). The lower limit of detection of this kit is
1.95 pg/ml.
Statistical analysis
For comparisons of differences between three or more
groups, a Kruskal-Wallis test was used, followed by
Dunn’s post-test for multiple comparisons. When two
groups were compared, a Mann-Whiney U test was per-
formed for continuous variables, and a χ2 or Fisher’s
exact test was used for discrete variables. The strength
of association between variables was determined using
Spearman’s correlation coefficient. All statistical analyses
were performed using Prism 6 software (GraphPad Soft-
ware, La Jolla, CA, USA).
Results
A significant number of ANA+ participants without a
SARD diagnosis have elevated levels of IFN-induced gene
expression
Participant demographics are shown in Table 1. There
were no significant differences in the sex, age or pro-
portion of participants taking anti-malarials between
groups. Several of the asymptomatic ANA+ individuals
were taking anti-malarials for symptoms (fatigue, arth-
ralgia/myalgia) that could not be definitively attributed
to SARD. Although participants with early SARD could
be within 2 years of receiving their diagnosis, owing to
the requirement for no prednisone or DMARD treat-
ment, the majority of patients were recruited at initial
presentation, with the exception of patients with SS
(≤5 years from symptom onset).
IFN-induced gene expression was first assessed using
the IFN5 score, the sum of normalized gene expression
for five genes that are increased in multiple SLE patient
peripheral blood mononuclear cell subsets [21]. Asymp-
tomatic and UCTD non-SARD ANA+ participants had
Table 1 Study participant characteristics
Healthy control
subjects (n = 20)
ANA+ no













Female sex, n (%) 18 (90) 37 (97.4) 27 (96.4) 54 (93.1) 24 (92.3) 6 (100) 21 (91.3) 3 (100)
Age, years, mean ± SD 41 ± 12.4 44.1 ± 14.3 47.5 ± 15.4 51.5 ± 14.4 52.8 ± 14.7 39 ± 12.3 54.8 ± 12.7 39.3 ± 6.6
Anti-malarials, n (%) 0 (0) 5 (13.2) 4 (14.3) 7 (12.1) 2 (7.7) 2 (33.3) 2 (8.7) 1 (33.3)
Ethnicity, n (%)
Caucasian 9 (45) 23 (60.5) 20 (71.4) 41 (70.7) 18 (69.2) 4 (66.7) 17 (73.9) 2 (66.7)
African 1 (5) 4 (10.5) 3 (10.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Asian 1 (5) 1 (2.6) 3 (10.7) 3 (5.2) 1 (3.8) 0 (0) 2 (8.7) 0 (0)
Southeast Asian 3 (15) 5 (13.2) 0 (0) 7 (12.1) 3 (11.5) 2 (33.3) 2 (8.7) 0 (0)
Filipino 4 (20) 1 (2.6) 1 (3.6) 4 (6.9) 3 (11.5) 0 (0) 0 (0) 1 (33.3)
Hispanic 1 (5) 1 (2.6) 1 (3.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other 1 (5) 3 (7.9) 0 (0) 3 (5.2) 1 (3.8) 0 (0) 2 (8.7) 0 (0)
Specific antibodies, n (%)
dsDNA 0 (0) 2 (5.3) 4 (14.3) 9 (15.5) 3 (11.5) 2 (33.3) 3 (13.0) 1 (33.3)
Ro 0 (0) 7 (18.4) 8 (28.6) 30 (51.7) 4 (15.4) 3 (50) 23 (100) 0 (0)
La 0 (0) 2 (5.3) 4a (14.3) 18 (31.0) 0 (0) 1 (16.7) 17 (73.9) 0 (0)
Sm 0 (0) 0 (0) 2 (7.1) 3 (5.2) 0 (0) 2 (33.3) 0 (0) 1 (33.3)
Sm/RNP 0 (0) 0 (0) 5 (17.9) 6 (10.3) 2 (7.7) 2 (33.3) 0 (0) 2 (66.7)
RNP 0 (0) 4 (10.5) 4 (14.3) 8 (13.8) 2 (7.7) 3 (50) 1 (4.3) 2 (66.7)
Scl-70 0 (0) 0 (0) 2 (7.1) 10 (17.2) 7 (26.9) 1 (16.7) 2 (8.7) 0 (0)
Jo-1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Centromere 0 (0) 1 (2.6) 1 (3.6) 17 (29.3) 14 (53.8) 1 (16.7) 1 (4.3) 1 (33.3)
Chromatin 0 (0) 2 (5.3) 4 (14.3) 6 (10.3) 1 (3.8) 3 (50) 0 (0) 2 (66.7)
Abbreviations: ANA Anti-nuclear antibody, UCTD Undifferentiated connective tissue disease, SARD Systemic autoimmune rheumatic disease, SSc Systemic sclerosis,
SS Sjögren’s syndrome, SLE Systemic lupus erythematosus, DM Dermatomyositis, MCTD Mixed connective tissue disease, dsDNA Double-stranded DNA, Sm Smith,
RNP Ribonuclear protein
aAll patients that were anti-La antibody positive were anti-Ro antibody positive, except for 1 patient with UCTD
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elevated levels of IFN-induced gene expression as com-
pared with ANA− HC (Fig. 1a). Although the mean
IFN5 score was lower in non-SARD ANA+ participants
than in patients with SARD, a number of individuals in
both non-SARD groups had levels comparable to those
seen in SARD. Overall, 36.8% of asymptomatic ANA+
subjects and 50% of patients with UCTD had IFN5
scores that were >2 SD above the mean for HC. Treat-
ment with anti-malarials did not appear to be associated
with any consistent differences in IFN5 levels. One of
five ANA+ individuals without SARD clinical diagnostic
criteria and two of four patients with UCTD taking anti-
malarials had high IFN5 levels in the same range as
those patients who were not on treatment. Of note, high
IFN5 scores were seen not only in those patients re-
ferred to a rheumatologist but also in individuals re-
cruited as HC who were subsequently reclassified as
ANA+ following ANA testing. In early SARD, 65.5% of
patients had elevated IFN5 scores (SSc 42.3%, SS 82.6%,
SLE 80.3%, MCTD/DM 100%), with patients with SSc
having lower IFN5 scores than those in the other SARD
groups.
There was no association between age or sex and
IFN5 levels in any of the ANA+ groups. With regard to
ethnicity, as shown in Table 1, the majority of study par-
ticipants were Caucasian. Previous work has indicated
that high levels of IFN are more likely to be driven by
autoantibodies in individuals of non-European ancestry
Fig. 1 Levels of interferon (IFN)-induced gene expression in the participant subsets, stratified by diagnosis. a IFN-induced gene expression was
quantified in whole peripheral blood RNA using NanoString technology and the normalized levels of five ubiquitously expressed IFN-induced
genes summed to produce an IFN5 score. Results to the left of the figure are shown for healthy control subjects (Control), individuals who were
asymptomatic anti-nuclear antibody–positive (ANA+), and patients who had undifferentiated connective tissue disease (UCTD) and early systemic
autoimmune rheumatic disease (SARD). Significant differences from healthy control subjects are indicated as * p < 0.05, ** p < 0.01 and *** p <
0.001. Results to the right of the figure show the IFN5 scores for the different early SARD patient subsets with the significant differences between
groups indicated. b IFN5 scores for different ANA+ subject subsets, stratified by ethic group. c Expression levels of two IFN-β-induced genes
(EIF2AK2 and PLSCR1) and BAFF in whole peripheral blood. Significant differences from healthy control subjects are indicated. d Correlation be-
tween EIF2AK2 and BAFF levels and IFN5 score for the different ANA+ subsets. Solid lines indicate linear regression curves. For all panels, dashed
lines represent 2 SD above the mean for healthy control subjects. e Correlation between serum IFN-α levels as measured by enzyme-linked im-
munosorbent assay and IFN5 scores for the different ANA+ subsets. Solid lines indicate linear regression curves. SSc Systemic sclerosis, SS Sjögren’s
syndrome, SLE Systemic lupus erythematosus, DM Dermatomyositis, MCTD Mixed connective tissue disease
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who have SLE [22, 23]. Therefore, to assess whether
there was an association between ethnicity and IFN-
induced gene expression, the IFN5 score was compared
between Caucasian subjects and those of all other eth-
nicities. As shown in Fig. 1b, within the subset of ANA+
individuals lacking SARD classification criteria, the mean
IFN5 score was higher in non-Caucasian subjects than
in Caucasian subjects. A similar non-significant trend
was seen for patients with UCTD, but this was lost in
patients with early SARD. Notably, not only African but
also Asian and Southeast Asian ethnicities were enriched
in the non-SARD subgroup of individuals with high
IFN5 scores.
It has been suggested that the IFN-induced genes that
are typically included in composite IFN scores (includ-
ing those in the IFN5 score) are driven predominantly
by IFN-α and may reflect a weaker IFN signature than
genes contained in clusters that may be driven by other
IFNs, such as IFN-β [17]. Therefore, to determine
whether the IFN signature seen in ANA+ individuals
that lack a SARD diagnosis differs from that seen in
early SARD, expression levels of two genes that are
contained within the cluster of genes that have been re-
ported to be induced by IFN-β and elevated in patients
with SLE who have higher levels of IFN-induced gene
expression [17], EIF2AK2 and PLSCR1, were examined.
In addition, to explore whether the levels of IFN in pa-
tients without SARD were sufficient to induce other cy-
tokines/chemokines in vivo, peripheral blood BAFF
expression was assessed. The levels of all three genes
were significantly elevated in patients with early SARD
(Fig. 1c) and showed a moderate (BAFF) to strong
(EIF2AK2 and PLSCR1) correlation with the IFN5 score
(Fig. 1d and data not shown). Although the mean levels
of these genes were not significantly increased in
asymptomatic ANA+ individuals or patients with
UCTD (Fig. 1c), the same strong correlation between
their expression levels and IFN5 scores was seen
(Fig. 1d), with a significant proportion of both subsets
of subjects having levels >2 SD above the mean for HC
(percent elevated EIF2AK2, PLSCR1 and BAFF: asymp-
tomatic ANA+ 34.2%, 18.4%, and 28.6%, respectively;
UCTD 50%, 35.7% and 25%, respectively). These find-
ings indicate strong induction of IFN-induced genes in
a subset of non-SARD ANA+ individuals and suggest
that the IFN-induced gene expression observed in a sig-
nificant proportion of ANA+ individuals without SARD
does not differ quantitatively or qualitatively from that
observed in patients with early SARD or that previously
reported for patients with SLE [17].
Previous data suggest that there is a moderate correl-
ation between serum IFN activity and IFN-induced gene
expression in SLE. Therefore, to determine whether the
IFN-induced gene expression observed in individuals
with early SARD and ANA+ individuals without SARD is
similarly correlated with serum IFN levels, we measured
serum IFN-α using a high-sensitivity enzyme-linked im-
munosorbent assay that detects all IFN-α subtypes. As
shown in Fig. 1e, there was a moderate correlation be-
tween serum IFN-α levels and IFN5 scores in the early
SARD and both non-SARD ANA+ groups. Notably, des-
pite the use of a high-sensitivity assay, serum levels of
IFN-α were below the limit of detection for all samples
from individuals with IFN5 scores <50,000, regardless of
diagnosis. There was no difference between the different
ANA+ groups in the proportion of individuals with
scores greater than this who had detectable levels of
serum IFN-α, indicating that ANA+ individuals without
SARD who had high IFN5 scores are just as likely to
have elevated levels of serum IFN-α as those with early
SARD.
In ANA+ participants lacking a SARD diagnosis, the levels
of IFN-induced gene expression correlate with serologic
findings
To determine whether differences in the levels of IFN-
induced gene expression were due to variations in the
ANA titre and the type and number of specific autoanti-
bodies, the association between the IFN5 score and these
serologic variations was assessed. Figure 2a shows the
ANA titres in each ANA+ participant subset. The mean
ANA titre was significantly lower in asymptomatic ANA+
individuals than in those with early SARD. There was
no association between ANA titre and ethnicity in
any of the groups examined. When all ANA+ individ-
uals were examined, there was a modest correlation
between ANA titre and IFN5 levels (r = 0.38, p <
0.0001). This appeared to be driven by the non-SARD
ANA+ subset, and particularly the asymptomatic
group (Fig. 2b and c). In the asymptomatic ANA+
group, this correlation remained present when just
the subset of individuals with no specific autoanti-
bodies was examined (r = 0.609, p = 0.0021).
Fifty percent of non-SARD participants had at least
one specific autoantibody, with the type and prevalence
of specific autoantibodies varying somewhat between the
different ANA+ groups (Table 1). Within each patient
group, the number of different autoantibody specificities
detected for asymptomatic ANA+ individuals or patients
with UCTD was significantly lower than that observed
in patients with early SARD (Fig. 3a), and patients with
UCTD had significantly more autoantibody specificities
than asymptomatic ANA+ individuals (p = 0.016). There
was no association between the number or type of auto-
antibody specificities and ethnicity. Although there was
a trend to a higher mean IFN5 score in the subset of
participants without SARD who had at least one specific
autoantibody as compared with none (42,170 ± 53,422
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vs. 16,421 ± 18,732, p = 0.088), elevated IFN5 scores were
still seen in 33% of individuals with no specific autoanti-
bodies. This proportion did not differ significantly from
the proportion of individuals with at least one specific
autoantibody who had high IFN5 scores (48.5%). Never-
theless, in both individuals without SARD and those
with early SARD, there was a moderate correlation be-
tween the number of different autoantibody specificities
and the IFN5 score (Fig. 3b), and this was also seen in
the UCTD subset (Fig. 3c). Similar findings were ob-
served for the association between the number of differ-
ent autoantibody specificities and serum IFN-α levels in
these groups (early SARD: r = 0.462, p = 0.0011; non-
SARD: r = 0.539, p < 0.0001; UCTD: r = 0.668, p =
0.0002).
To investigate whether particular types of autoanti-
bodies are associated with elevated levels of IFN-induced
gene expression, autoantibody profiles were clustered
into three groups: Ro and/or La, RNP and/or Sm/RNP
and/or Sm, and chromatin and/or dsDNA. Only the
presence of anti-Ro and/or anti-La antibodies demon-
strated a significant association with IFN5 levels, and
this was seen for all ANA+ groups (Fig. 4). In Ro+ indi-
viduals, there was no correlation between the levels of
anti-Ro antibodies and IFN5 levels, and the IFN5 levels
were not significantly different between participants with
and without anti-La antibodies (data not shown). Con-
sistent with the association between anti-Ro and/or anti-
La antibodies and high IFN5 levels, the majority (18 of
26) of individuals without SARD who had elevated IFN5
levels had a speckled pattern of immunofluorescence in
their ANA test.
Although the IFN5 levels in asymptomatic ANA+ indi-
viduals that were anti-RNP and/or anti-Sm/RNP and/or
anti-Sm positive, or anti-chromatin and/or anti-dsDNA
positive were lower than those observed for similarly
positive patients within the UCTD and early SARD
groups, the number of different autoantibody specific-
ities associated with these autoantibodies differed mark-
edly between these groups. All of the individuals in the
asymptomatic ANA+ group had only one specific auto-
antibody (either RNP, dsDNA or chromatin), whereas
the number of different autoantibody specificities ranged
from one to five for UCTD (mean 2.7 for Sm/RNP and
3.1 for DNA) and from one to seven for early SARD
(mean 4 for Sm/RNP and 3 for DNA), raising the possi-
bility that the differences in IFN5 levels between groups
are associated with differences in the autoantibody pro-
file rather than the presence or type of clinical disease
activity. Notably, the majority of the ANA+ individuals
with detectable IFN-α levels had anti-Ro with or without
anti-La antibodies (2 of 3 asymptomatic ANA+, 5 of 7
Fig. 2 Association between anti-nuclear antibody (ANA) titre and interferon (IFN)-induced gene expression. a ANA titres in asymptomatic ANA+
individuals, patients with undifferentiated connective tissue disease (UCTD) and patients with early systemic autoimmune rheumatic disease
(SARD). Significant differences from patients with early SARD are indicated as *** p < 0.001. b Association between IFN5 score and ANA titre in
participants with non-SARD (asymptomatic ANA+ and UCTD) and those with early SARD. c Association between IFN5 scores and ANA titre for
asymptomatic ANA+ participants and patients with UCTD. Significant associations are indicated
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UCTD and 13 of 16 early SARD), with most of the
remainder having a combination of anti-Sm/RNP with anti-
RNA and anti-chromatin antibodies, with or without anti-
Sm antibodies (2 of 7 UCTD and 2 of 16 early SARD).
Associations between high IFN5 score and clinical
symptoms in ANA+ individuals without SARD
To further explore the potential clinical significance of
elevated levels of IFN-induced gene expression in the
ANA+ non-SARD groups, the association between clin-
ical symptoms and IFN5 levels was examined. For indi-
viduals who were ANA+ and lacked any clinical SARD
classification criteria, we investigated whether there was
an association between the clinical symptoms prompting
ANA testing and the IFN signature. Of the 38 individ-
uals in this group, 10 were found to be ANA+ after re-
cruitment as HC, 4 after delivery of an infant with
neonatal lupus or congenital heart block (all anti-Ro
antibody–positive), 15 following investigation for arth-
ralgia/myalgia, 6 following investigation for skin symp-
toms and 3 following investigation for other symptoms
(1 eye symptoms, 1 white digits in the absence of
Raynaud’s phenomenon and 1 headache). The frequency
of elevated IFN5 scores varied in these groups, with
100% of Ro+ mothers, 40% of ANA+ HC, 33% of individ-
uals with skin symptoms, 20% of individuals with arth-
ralgia/myalgia and none of the individuals with other
symptoms having high IFN5 levels. Amongst those indi-
viduals with elevated IFN5 scores, the highest levels
were seen in Ro+ mothers (range 30,536–129,159). No
difference was seen between the IFN5 levels in those in-
dividuals who were originally recruited as HC (range
26,074–71,028) and those who had non-specific symp-
toms (range 20,382–73,333).
Of the 28 patients with UCTD, 6 had symptoms sug-
gestive of SSc (pre-SSc; Raynaud’s phenomenon,
oesophageal dysmotility, telangiectasia and digital ulcers)
in the absence of scleroderma/sclerodactyly, 2 had sicca
symptoms and the remainder had symptoms suggestive
of incomplete lupus syndrome (ILE; arthritis, lupus
rashes, vasculitic skin lesions, pleuritis, idiopathic
thrombocytopenic purpura, pericarditis and mucocuta-
neous ulcers). Notably, none of the patients with pre-SSc
had high IFN5 levels, whereas 50% of patients with ILE
and 100% of patients with sicca symptoms (both Ro+)
had high IFN5 levels.
Although we plan to follow all patients without SARD
on a yearly basis or earlier if new symptoms develop, we
currently have limited follow-up data on these individ-
uals because many were fairly recently recruited. One-
year follow-up information is available for 19 of the
ANA+ individuals who lacked clinical SARD criteria.
Four patients have developed SARD symptoms, three of
whom developed inflammatory arthritis (two were anti-
Fig. 3 Association between the number of different anti-nuclear antibody (ANA) specificities detected and interferon (IFN)-induced gene expression.
a The number of different ANA specificities detected using the BioPlex® 2200 system in asymptomatic ANA+ individuals, participants with
undifferentiated connective tissue disease (UCTD), and participants with early systemic autoimmune rheumatic disease (SARD). Significant
differences from patients with early SARD are indicated as * p < 0.05, *** p < 0.001. Association between IFN5 score and the number of
autoantibodies detected in (b) non-SARD (asymptomatic ANA+ and UCTD) and early SARD participants and in (c) asymptomatic ANA+
individuals and participants with UCTD. Significant associations are indicated
Wither et al. Arthritis Research & Therapy  (2017) 19:41 Page 7 of 11
Ro+, both with high IFN levels, one of whom had detect-
able IFN-α) and one of whom developed myositis (anti-
RNP+ with a normal IFN5 level). Although there was a
trend for an increased proportion of individuals with
high (2 of 5) as compared with normal (2 of 14) IFN5
levels who developed SARD symptoms, this did not
achieve statistical significance. Within the UCTD subset,
1-year follow-up information is available for 23 patients.
Of these, seven have developed new SARD symptoms,
six of whom have sufficient classification criteria for a
diagnosis (three with SLE, one with SS, one with SSc
and one with rheumatoid arthritis). The remaining pa-
tient, who was anti-Ro+ and who presented with a tran-
sient episode of inflammatory arthritis, developed new
onset of sicca symptoms. Of the 12 patients with high
IFN5 scores, 4 progressed (2 to SLE, 1 to SS and 1 with
new sicca symptoms, and 3 of whom had high serum
levels of IFN-α). This rate of progression was not signifi-
cantly different from that of the 11 patients with normal
IFN5 scores, among whom 3 progressed (1 each to
rheumatoid arthritis, SSc and SLE). There was no associ-
ation between age and the risk of progression in either
of the ANA+ non-SARD groups, either as a whole or
when the subset of individuals with high IFN5 scores
was examined.
Discussion
Type I IFNs have been proposed to play an important
role in the pathogenesis of SARD through a potential
feed-forward mechanism in which elevated levels of nu-
clear antigen–containing immune complexes lead to en-
hanced production of type I IFNs, which in turn further
disturbs B- and T-cell tolerance mechanisms promoting
production of ANAs [24]. Consequently, it has been hy-
pothesized that elevated levels of type I IFNs may ac-
company and drive the conversion from pre-clinical to
symptomatic autoimmunity in SARD [24]. In support of
this concept, administration of type I IFNs to patients
with hepatitis or malignancy leads to development of
SARD in a small subset of patients, which abates once
Fig. 4 Correlation between interferon (IFN)-induced gene expression and the presence of specific anti-nuclear antibodies (ANA). The levels of specific
ANA were measured using the BioPlex® 2200 ANA screening system, and participants were stratified on the basis of presence or absence
of anti-Ro and/or anti-La (Ro/La), anti-Smith (anti-Sm) and/or anti-Sm/ribonuclear protein (RNP) and/or anti-RNP (Sm/RNP), or anti-double-stranded
(anti-dsDNA) and/or anti-chromatin (DNA). Correlation between each cluster of autoantibodies and the IFN5 score for (a) all ANA+ participants and the
non-systemic autoimmune rheumatic disease (SARD) and early SARD subsets and (b) asymptomatic ANA+ individuals and participants with
undifferentiated connective tissue disease (UCTD). Significant correlations are indicated. Dashed lines in each figure represent 2 SD above
the mean for healthy control subjects
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treatment is discontinued [25, 26]. In addition, the ma-
jority of patients with SARD have blood changes consist-
ent with elevation of type I IFNs [11–16], and a number
of SARD genetic risk variants have been shown to en-
hance the production of and/or the response to these
IFNs [27]. Although there is some data suggesting that
elevations of levels of serum IFN-α are present in a sub-
set of healthy family members of patients with SLE and
display features consistent with a heritable trait [28], it is
not known whether elevation in type I IFNs precedes
and/or predicts the conversion to symptomatic auto-
immunity in ANA+ individuals. In this study, as a pre-
liminary means of addressing this question, we asked
whether increased levels of type I IFNs, as measured by
an IFN signature, can be seen in ANA+ individuals who
either lack or have insufficient criteria for a SARD diag-
nosis. We show that approximately one-third of ANA+
individuals lacking any clinical SARD criteria have ele-
vated levels of IFN-induced gene expression. Although it
could be argued that these individuals were not truly
asymptomatic because they had clinical symptoms that
led to their ANA testing, the same findings were ob-
served for clinically asymptomatic Ro+ mothers and in-
dividuals who were recruited as HC but were
subsequently found to be ANA+. Thus, the presence of
an IFN signature clearly is not temporally associated
with the presence of clinical SARD symptoms in a sig-
nificant subset of ANA+ individuals. Notably, compar-
able elevations in IFN-induced gene expression were not
seen in any of the ANA− HC (only one of whom has an
IFN5 score slightly above the normal range). Indeed, all
HC who had high IFN signatures were subsequently
found to have ANAs, a finding that suggests that the ele-
vated levels of IFN-induced gene expression are closely
associated with ANA production. To some extent, these
findings recapitulate those seen in individuals with
established SLE, in whom the presence of an IFN signa-
ture was more closely associated with autoantibodies
than with clinical disease activity [22, 29].
Elevated levels of IFN-induced genes were also seen in
a significant subset of patients with UCTD. Previous
work has shown that about 50% of patients with ILE
have elevated IFN signatures [30], and our findings are
consistent with these observations. However, we have
extended this work by examining not only patients with
ILE but also other patients with pre-SARD. We show
that patients with pre-SS have elevated IFN signatures,
whereas these changes are not seen in patients with pre-
SSc. Although a significant proportion of patients with
SSc with established disease (47–68%) are reported to
have elevated IFN-induced gene expression in their per-
ipheral blood, the levels of expression are generally
lower than those seen in SLE [11, 15]. In the present
study, we show that only about 35% of patients with
newly diagnosed SSc have an elevated IFN signature in
their whole peripheral blood, with lower mean levels in
these patients than in other early SARD groups. This
finding, taken together with the lack of IFN signature
elevation in patients with pre-SSc, one of whom subse-
quently developed SSc, suggests that elevations in IFN
may occur later in the disease course of SSc and/or may
play a less important pathogenic role than in SLE and
SS. However, given the relatively small number of pa-
tients with SSc examined, this finding requires validation
in an independent cohort of patients with newly diag-
nosed SSc.
In ANA+ individuals without SARD, elevated levels of
IFN-induced gene expression correlated with serologic
findings. Although previous researchers examining pa-
tients with established SARD have shown that elevations
in anti-chromatin, anti-dsDNA, anti-RNP, anti-Ro, anti-
La and anti-Scl70 antibodies are associated with elevated
levels of IFN-induced gene expression [11, 14–16, 22,
24, 31, 32], amongst the asymptomatic ANA+ individuals
with detectable specific anti-nuclear autoantibodies, only
anti-Ro and/or anti-La antibodies were associated with
an elevated IFN signature. Indeed, of the seven individ-
uals with these autoantibodies, only one did not have a
high IFN5 level. In addition, one HC who was ANA−
and therefore did not satisfy our inclusion criteria was
anti-Ro+ and had a high IFN5 level (67,233). Thus, anti-
Ro antibodies are closely associated with type I IFN ex-
pression even in HC.
However, not all anti-Ro+ individuals had high levels
of IFN-induced gene expression, including a subset of
those with UCTD or early SARD, indicating that other
factors are also required to lead to the generation of IFN
in these individuals. Previous work has shown that pro-
duction of IFN in anti-Ro+ individuals is associated with
the lupus risk variant of IRF5 [24, 33], and thus these in-
dividuals may lack genetic variants that promote IFN
production. Alternatively, these individuals may lack a
source of the nuclear autoantigens that are presumably
required to produce the immune complexes that drive
IFN production by plasmacytoid dendritic cells. It is cur-
rently unclear what processes lead to the production of
these immune complexes in asymptomatic ANA+
individuals.
Our findings contrast with the results of a previous
study that suggested that IFN levels are not elevated in
asymptomatic Ro+ individuals [34]. In that study, the
ability of serum from anti-Ro+ mothers of infants with
neonatal lupus to promote IFN-induced gene expression
in an indicator cell line was examined (serum IFN activ-
ity). Serum IFN activity levels in 24 asymptomatic
mothers were found to be similar to those of healthy
control subjects, whereas 25–75% of mothers with pre-
SLE, SLE, pre-SS or SS had elevated serum IFN activity.
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The origin of the differences between the two studies
likely lies in the different techniques used to measure
IFN, with serum IFN activity reflecting the amount of
type I IFN in the serum, whereas an IFN signature mea-
sures exposure of peripheral blood cells to type I IFN,
which could occur in either the tissues or blood. In
keeping with previous work indicating a modest correl-
ation between serum IFN activity and the IFN signature
in SLE [35], we found a moderate correlation between
serum IFN-α levels and IFN-induced gene expression as
measured by the IFN5 score in all ANA+ groups. Not-
ably, increased serum IFN-α levels were detected only in
ANA+ individuals with very high IFN5 scores and dem-
onstrated considerable variability between samples with
similar scores in this range. It is currently unclear
whether this variability represents differences in the site
of, and/or the immunologic mechanism leading to, IFN
production. Nevertheless, in contrast to the previous
study [34], we found that IFN-induced gene expression,
and in some cases detectably elevated levels of serum
IFN-α, could be just as high in asymptomatic anti-Ro+
individuals as in patients with early SARD, suggesting
that the amount of IFN to which their peripheral blood
cells are exposed is similar.
Our results are in agreement with those reported in a
recent publication on the temporal relationship between
cytokine elevation, autoantibodies and the development
of lupus classification criteria in a longitudinally
followed cohort prior to the development of SLE. As ob-
served in that study, we also found that immunologic
changes indicating elevated levels of type I IFN were not
seen in the absence of ANAs and correlated with the
number of autoantibody specificities that were present
[36]. However, in contrast to that study, we saw elevated
IFN5 scores in individuals who lacked specific autoanti-
bodies as detected by the BioPlex® 2200 ANA screening
system. One reason for this apparent discordance may
be that the majority of our study participants were Cau-
casian, whereas those in the study by Munroe et al.
study [36] were predominantly of African or other non-
Caucasian descent. Previous work has shown that the
BioPlex® 2200 ANA screening system is significantly less
able to detect ANAs in Caucasians than the ANA de-
tected by immunofluorescence, whereas the agreement
between these two assays is much better for other ethnic
groups [37]. Nevertheless, our results provide further
support for the concept that elaboration of type I IFN
occurs as a consequence of autoantibody production ra-
ther than as an initial etiologic mechanism that leads to
their generation.
Despite the short duration of follow-up for the individ-
uals without SARD in our study, approximately 20% of
asymptomatic ANA+ individuals developed SARD symp-
toms/signs and 30% of UCTD patients evolved, with the
majority meeting classification criteria for a SARD. Al-
though there was an insufficient number of progressing in-
dividuals to determine whether progression to any SARD
or a specific SARD might occur more frequently in individ-
uals with elevated levels of IFN-induced gene expression, it
is clear that an increased IFN5 score is not strongly associ-
ated with imminent progression over the next year to
SARD. Conversely, progression to a SARD classification oc-
curred in some individuals in the absence of elevated IFN-
induced gene expression (confirming and extending the
findings of Munroe et al. for SLE [36]).
Conclusions
An IFN signature that is quantitatively and qualitatively
similar to that seen in SARD is found in a significant pro-
portion of ANA+ individuals who lack or have insufficient
clinical classification criteria for a diagnosis of SARD. In
these individuals, elevated levels of IFN-induced gene ex-
pression correlated with ANA titre and the presence of
anti-Ro antibodies, but they were not required for or pre-
dictive of clinical progression over the subsequent year.
Thus, it is unlikely that an elevated IFN signature will be
the sole predictive factor for SARD disease progression,
and additional novel biomarkers, or algorithms using exist-
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